Cited by — Trajectories of Plasma Epstein–Barr Virus DNA and Clinical Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD ‐ L1 Inhibitors: A Post‐Hoc Analysis of a Multicenter, Phase II Study

Cited by — Trajectories of Plasma Epstein–Barr Virus DNA and Clinical Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD ‐ L1 Inhibitors: A Post‐Hoc Analysis of a Multicenter, Phase II Study | ResearchHub - ResearchHub